Pierre Yves Guiavarch, Managing Director, Biomnis Group addressed the National Healthcare Conference on Marc h 24th 2011 in Dublin

1. The Biomnis Group National Healthcare Conference Burlington Hotel, March 24th 2011 Pierre-Yves Guiavarch, President & CEO Simon Chipperfield, International Director Réunion mensuelle DSC - BIOMNIS 15/09/2009

3. Reforming the Healthcare System

4. Pathology Reform in France – Consolidation at a Crossroads

5. Biomnis in Ireland

6. International Trends in Pathologywww.biomnis.com

9. Acquisition of « LABS » (Nice)

11. Creation of « BIOMNIS »

13. Acquisition of OpenLab (IT)www.biomnis.com

15. Dedicated to Clinical Pathology since 1897

16. 10m+ tests per annum

17. Expertise in all fields of Clinical Pathology (ISO 15189 accredited)

18. 2,500 in-house assays

19. Medically and scientifically led

20. 60+ consultant pathologists and over 1600 employees

21. International reach

22. 50+ countries referring tests

24. Specialised cold laboratory testing services, in all fields of Clinical Pathology:

27. 500 staff including 35 expert Pathologists

28. 10 000 m²

29. 10 000 patient requisitions / day => 18 000 tests / dayI. Overview of the Biomnis Group

30. I. Overview of the Biomnis Group Mycobacteria Department

32. 400 staff including 20 expert pathologists

33. 6000 m²

34. 10 000 patient requisitions /day => 18 000 tests / dayI. Overview of the Biomnis Group

35. Haematology I. Overview of the Biomnis Group

37. Full management of Hospital based clinical laboratories –

38. 10 hospital locations – 1000+ beds – supported by 4 labs

39. Point of Care Testing, Hot Labs and specialist referrals

40. Walk in patient Primary Care Laboratories - « Town Labs »

41. Paris, Lyon and Bordeaux regions

42. Forensic genetic testing

43. Specialist service for French Police

44. Temperature controlled logistics of biological samples

45. 500+ vehicles in own specialist medical logistics service across France & Irelandwww.biomnis.com I. Overview of the Biomnis Group

47. « TSE express medical »

48. 25 hubs

49. 4 regionalplatforms

50. 500 staffwww.biomnis.com I. Overview of the Biomnis Group Regional hubs Local hubs Central hubs Head quarters

52. Only Clinical Pathologists are allowed to run a laboratory

53. Hold a minimum of 75% of the voting rights

54. Restricted rules for operating a laboratory

55. Limited Geographic scope, minimum headcount, specific equipment, minimum surface area and requirement to perform 60% of tests on site

56. Other Features:

57. 40%+ of clinical pathology performed by private sector

58. Price regulation via a National Tariff structure

59. 2 main private specialist referral test laboratories – Biomnis and Cerba

60. c.4000 Town Laboratories – fragmented and relatively expensive2. Pathology Reform in France – At a Crossroads www.biomnis.com

62. Key findings from IGAS:

63. Inappropriateness of current regulations for opening a new laboratory and protection of clinical pathologist from any competition

64. Dysfunctional influence of the price regulation system

65. Reform should focus on high quality level at optimised cost

66. Mandatory accreditation of all laboratories

67. Thorough review of tariff nomenclature

68. Necessity to create larger players and platforms

69. Ballereau report required reform around 3 key axes:

70. Reaffirmation of the medical characteristic of clinical pathology

71. Systematic and mandatory accreditation system to improve quality

72. Cancellation of restrictions on laboratory shareholding structure

73. Target savings for next 5 years (2.5 to 3.5% per annum)2. Pathology Reform in France – At a Crossroads www.biomnis.com

75. Clinical pathology is a medical act – clinical pathologist has to be responsible for the entire testing process

76. Reduced regulation relating to laboratory operations

77. All laboratories required to obtain ISO 15189 by 2016 at the latest

78. Initially committed to opening the laboratories shareholding structure but postponed after clinical pathologists’ lobbying

79. Since the Bachelot Law:

80. Price reductions implemented

81. Rebates from specialist laboratories to Town Laboratories have been suppressed

82. Rebates to Public Hospitals (for up to 50% of the standard tariff) are being cancelled over 3 year period

83. Private sector has rapidly started to consolidate in the Town Labs sector

84. Combination of laboratories into regional clusters with hub and spoke model - 1 major lab technical platform and multiple collection centres2. Pathology Reform in France – At a Crossroads www.biomnis.com

86. Recent ECJ Ruling on shareholding structures

87. French National Assembly vote to repeal Ballereau Ordonnance

88. In spite of this fresh uncertainty part-way through a major reform programme, the market will continue to consolidate to achieve:

89. Larger higher volume regional laboratory platforms

90. Mandatory quality and accreditation standards

91. Better value for money

92. Whilst ensuring that clinical pathology remains a medically delivered service for the benefit of the patients2. Pathology Reform in France – At a Crossroads www.biomnis.com

94. « Methadone maintenance » clinics3. Biomnis in Ireland

96. Acquisition of Euromedic Lablink

97. Extension of test repertoire in Dublin Laboratory

98. Phase 1 technology transfer from France

99. 30% increase in Test Menu

100. Celebrating 20 years in business in Ireland in 2011

101. 20 new technical & scientific employees in 2010 – 70% graduates

102. Phase 2 technology transfer in 2011

103. Collaboration with Third-Level Institutes

104. Establishment of JVs with public sector partnerswww.biomnis.com

106. Lab test results are the major contributor to patient records

107. 65 year olds account for x6-9 more lab tests per head

108. It is estimated that pathology testing in US will increase c.90% by 2017In countries with ageing populations, there will be considerable pressure on Diagnostic Laboratory services due to ageing populations and an increasing reliance on pathology diagnostics www.biomnis.com

110. Greater use of automation and larger technical platforms

111. ICT integration into public health networks

112. Use of mobile devices

113. Higher volumes and lower prices

114. Market consolidation across the private sector in Europe and USA

115. Outsourcing and extensive use of the private sector as a partner with the public sector

116. Potential Global shortages of scientific staff

117. Standardisation of accreditation standard to ISO 15189

118. Development of genetic companion diagnostics and personalised medicinewww.biomnis.com

120. Staff shortages in medical science disciplines will drive need to change working practices

121. Automation and scaling of technical platforms can enable volume to be delivered at lower cost

122. We can learn from a number of international experiences and models already delivering rapid, high quality results that help clinicians diagnose, treat and monitor patient illnesses and diseaseswww.biomnis.com